CancerDrs

Lymphoma clinical trials in Missouri

32 actively recruiting lymphoma trials at 19 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Saint Luke's Hospital — Chesterfield, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Saint Luke's Hospital — Chesterfield, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • University of Missouri Children's Hospital — Columbia, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
  • University of Kansas Cancer Center - North — Kansas City, Missouri
  • University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
  • University of Kansas Cancer Center - North — Kansas City, Missouri
  • University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …

Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Missouri:
  • Research Site — Chesterfield, Missouri
  • Research Site — Springfield, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Missouri:
  • MidAmerica Cancer Care, LLC ( Site 0043) — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…

Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Missouri:
  • Washington University School of Medicine (Adults only) — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…

Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Missouri:
  • Washington University in St. Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonuni…

Sponsor: St. Louis University
NCT ID: NCT03823534
Sites in Missouri:
  • Saint Louis University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Heartland Regional Medical Center — Saint Joseph, Missouri
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Mercy Hospital Saint Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06649812
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
  • Siteman Cancer Center at Christian Hospital — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
  • Siteman Cancer Center at Christian Hospital — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…

Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Missouri:
  • Washington University, St. Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…

Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Missouri:
  • Washington University School of Medicine Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Missouri:
  • Children's Mercy Hospital ( Site 1024) — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

Sponsor: T. John Winhusen, PhD
NCT ID: NCT06651177
Sites in Missouri:
  • The Gibson Center for Behavioral Change — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) t…

Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06238648
Sites in Missouri:
  • Siteman Cancer Center at Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
  • Siteman Cancer Center at Christian Hospital — St Louis, Missouri
View on ClinicalTrials.gov →

Showing 25 of 32 trials with sites in Missouri. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12